ESTRO 2023 - Abstract Book

S1177

Digital Posters

ESTRO 2023

Materials and Methods Patients with unfavorable intermediate and high risk prostate cancer were recruited. Randomization was to prostate and seminal vesicles alone (Arm 1) 36.25 Gy in 5 fractions versus the same treatment plus ENI at a dose of 25 Gy as with a simultaneous boost (Arm 2). The primary outcomes was Recruitment (Percentage of screened patients eligible recruited in six months) and Treatment protocol Fidelity, defined as protocol compliance or minor deviation for PTV/CTV and organ at risk (OAR) coverage. Recruitment success was defined as 80% and Treatment protocol Fidelity as 60%. The secondary outcome was acute genitourinary (GU) and gastrointestinal (GI) adverse events grade 3 or greater, according with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, 1 month after the end of radiotherapy. Results From Aug 2021 to Jan 2022, 30 patients met the inclusion criteria and of these four declined to participate. Eleven patients were randomized to Arm 1 and thirteen to Arm 2. Recruitment was 86.7%. Four patients did not receive allocated treatment due to intercurrent disease (2) or severe incontinence (2). Finally, nine and eleven patientes recived treatment to wich they were randomized. The characteristics of patients are summarized in Table 1. None and two patients report major deviations in PTV prostate+seminalvesicle coverage in Arm 1 and Arm 2, respectively; no major deviations in CTV prostate+seminalvesicle, PTV pelvis and CTV pelvis were found in Arm 2. Regarding OAR, 3 and 2 patients had major deviations on the rectum in Arm 1 and Arm 2, respectively. Treatment protocol fidelity for PTV/CTV was 100% and 81.8% in Arm1 and Arm2, respectively, and for OAR 66.7% and 81.8% in Arm 1 and Arm 2, respectively. At one month after the end of treatment one patient reported acute GI toxicity grade 3 (diarrhea) in Arm 2, without acute grade 3 or higher GU toxicity. No grade 3 or higher GI and GU was present in Arm1.

Conclusion Previously defined recruitment and treatment fidelity standards were met. Conducting a randomized study in this scenario is feasible. Acute toxicity is low. Longer follow-up is needed to assess adherence and long-term toxicity and efficacy.

PO-1455 Impact of pelvic irradiation on fiducial tracking prior to SBRT for high-risk prostate cancer

J. Lischalk 1 , V.F. Santos 1 , M. Coakley 2 , M. Akerman 3 , A. Sanchez 4 , C. Mendez 4 , T. Carpenter 4 , A. Katz 5 , A. Corcoran 5 , H.Y. Marans 6 , O. Clancey 7 , M. Witten 7 , S.S. Taneja 6 , J.A. Haas 4 1 Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Radiation Oncology, New York, USA; 2 Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Radiation oncology, New York, USA; 3 NYU Langone Hospital - Long Island, Mineola, Research and Academic Center, Mineola, USA; 4 Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Radiation Oncology, Mineola, USA; 5 Perlmutter Cancer Center at New York University Langone Hospital - Long Island, Urology, Mineola, USA; 6 NYU Grossman School of Medicine, Urology, New York, USA; 7 Perlmutter Cancer Center at New York University Langone Hospital-Long Island, Radiation Oncology, Mineola, USA Purpose or Objective Pelvic nodal irradiation is commonly utilized in the management of high-risk prostate cancer. A novel method of dose escalation in lieu of an LDR brachytherapy implant is the use of a 3-fraction robotic radiosurgical SBRT boost using fiducial tracking. This theoretically achieves more comprehensive coverage of extracapsular extension or seminal vesicle invasion, which can be common in high-risk disease. In the present study, we investigate the impact of upfront nodal irradiation on subsequent fiducial tracking for the SBRT boost portion of treatment.

Materials and Methods